

INFORMAZIONI PERSONALI

Giovanni Randon – RNDGNN89C07G224J

 Via Giacomo Venezian, 1 – 20133 Milano

 +39 0223903841

 giovanni.randon@istitutotumori.mi.it

Sesso M | **Data di nascita** 07/03/1989 | **Nazionalità** Italiana

Dal 01/12/2021 **Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, INT**
Via Venezian 2, 20133 Milano

Oncologo Medico

Esperienza nella gestione di pazienti affetti da neoplasie gastrointestinali e neuroendocrine come sub-investigatore in più di 30 studi clinici interventistici di fase 1, 2 e 3.

EDUCAZIONE
01/11/2016 – 31/10/2021

Specializzazione in Oncologia Medica
Università di Milano
Scuola di Specializzazione in Oncologia Medica
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, INT
Via Venezian 2, 20133 Milano (70/70 cum laude)

Specializzando Oncologia Medica

2008-2015 **Università di Padova**
Laura in Medicina e Chirurgia (110/110)

2013-2015 **Istituto Oncologico Veneto IOV-IRCCS**
Oncologia 2

Studente frequentatore

2003-2008 **Liceo Classico “Tito Livio”, Padova**
Diploma di liceo classico (100/100)

Lingua madre Italiano

Altre lingue parlate

	COMPRENSIONE		PARLATO		SCRITTURA
	ascolto	lettura	Capacità interazione	Forma nell'espressione	
INGLESE	C1	C1	C1	C1	C1
First Certificate English (2007)					
TEDESCO	B1	B1	B1	B1	B1
Goethe Zertifikat B1 (2008)					

Levels: A1/A2: Basic user - B1/B2: Independent user - C1/C2: Proficient user
Common European Framework of Reference for Languages

Patente di guida

B

Premi

Premio Giovani Ricercatori - Sezione Ricerca Traslazionale – 2021 per il lavoro: Randon G, et al. EGFR Amplification in Metastatic Colorectal Cancer; J Natl Cancer Inst 2021.

Appartenenza a società scientifiche

European society for clinical oncology (ESMO) dal 2018
Associazione italiana Oncologia Medica (AIOM) dal 2017

PUBBLICAZIONI

Pubmed link: <https://pubmed.ncbi.nlm.nih.gov/?term=giovanni+randon&sort=date>

1: **Randon G**, Nicoletto MO, Milite N, Muggia F, Conte P. Squamous cell carcinoma of the oral cavity in a woman with a 9-year history of ovarian cancer: is exposure to pegylated liposomal Doxorubicin a factor? *Oncologist*. 2014 Apr;19(4):429. doi: 10.1634/theoncologist.2013-0421. Epub 2014 Mar 25. PMID: 24668330; PMCID: PMC3983824.

2: Indraccolo S, **Randon G**, Zulato E, Nardin M, Aliberti C, Pomerri F, Casarin A, Nicoletto MO. Metformin: a modulator of bevacizumab activity in cancer? A case report. *Cancer Biol Ther*. 2015;16(2):210-4. doi: 10.1080/15384047.2014.1002366. PMID: 25607951; PMCID: PMC4623111.

3: Nicoletto MO, Baldoni A, Casarin A, **Randon G**, Nardin M, Baretta Z, Lardelli P, Nieto A, Alfaro V, Rigamonti C, Conte PF. Trabectedin plus pegylated liposomal doxorubicin: retrospective analysis in heavily pretreated platinum-sensitive ovarian cancer. *Tumori*. 2015 Sep-Oct;101(5):506-10. doi: 10.5301/tj.5000371. Epub 2015 Jun 18. PMID: 26108247; PMCID: PMC6166415.

4: Nicoletto MO, Casarin A, Baldoni A, Rulli E, Tasca G, Baretta Z, Artioli G, Lombardi G, Cappetta A, Floriani I, **Randon G**, Valpione S, Litta P, Conte P, Mocellin S, Aliberti C. Intraperitoneal Chemotherapy in Patients Pretreated

for Ovarian Cancer Matched with Patients Treated with Parenteral Chemotherapy. *Anticancer Res.* 2016 Dec;36(12):6541-6546. doi: 10.21873/anticancer.11256. PMID: 27919980.

5: Nichetti F, Lobefaro R, Pagani F, **Randon G**, Corti F, de Braud F, Celio L, Platania M. "Systemic strategy at the patient's service": a congress report on supportive care in oncology. *Tumori.* 2017 Jul 27:0. doi: 10.5301/TJ.2017.17342. Epub ahead of print. PMID: 28777425.

6: Cimminiello C, Indini A, Di Guardo L, Prisciandaro M, **Randon G**, Tolomio E, De Braud F, Del Vecchio M. Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experience. *Melanoma Res.* 2019 Jun;29(3):289-294. doi: 10.1097/CMR.0000000000000539. PMID: 30520799.

7: Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, **Randon G**, De Braud F, Del Vecchio M. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. *J Cancer ResClin Oncol.* 2019 Feb;145(2):511-521. doi: 10.1007/s00432-018-2819-x. Epub 2018 Dec 11. PMID: 30539281.

8: Pietrantonio F, Cotsoglou C, Fucà G, Lo Vullo S, Nichetti F, Milione M, Coppa J, Vaiani M, Alessi A, Prisciandaro M, Droz-Dit Busset M, Morano F, Corallo S, Lazzati S, Antista M, Mennitto A, **Randon G**, Raimondi A, Belfiore A, Padovano B, Perrone F, Mariani L, Di Bartolomeo M, de Braud F, Mazzaferro V. Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. *Clin Colorectal Cancer.* 2019 Mar;18(1):34-43.e6. doi: 10.1016/j.clcc.2018.11.004. Epub 2018 Nov 24. PMID: 30558859.

9: Cona MS, Lecchi M, Cresta S, Damian S, Del Vecchio M, Necchi A, Poggi MM, Raggi D, **Randon G**, Ratta R, Signorelli D, Vernieri C, de Braud F, Verderio P, Di Nicola M. Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies. *Cancers (Basel).* 2019 Feb 14;11(2):223. doi: 10.3390/cancers11020223. PMID: 30769874; PMCID: PMC6406250.

10: **Randon G**, Fucà G, Rossini D, Raimondi A, Pagani F, Perrone F, Tamborini E, Busico A, Peverelli G, Morano F, Niger M, Antista M, Corallo S, Saggio S, Borelli B, Zucchelli G, Milione M, Pruneri G, Di Bartolomeo M, Falcone A, de Braud F, Cremolini C, Pietrantonio F. Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. *Sci Rep.* 2019 Feb 27;9(1):2858. doi: 10.1038/s41598-019-39525-3. PMID: 30814645; PMCID: PMC6393680.

11: Raimondi A, Corallo S, Niger M, Antista M, **Randon G**, Morano F, Milione M, Kusamura S, Baratti D, Guaglio M, Cremolini C, Marmorino F, Di Bartolomeo M, Deraco M, De Braud F, Pietrantonio F. Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei. *Clin Colorectal Cancer.* 2019 Jun;18(2):e179-e190. doi: 10.1016/j.clcc.2019.03.002. Epub 2019 Apr 1. PMID: 31023524.

12: Sangaletti S, Talarico G, Chiodoni C, Cappetti B, Botti L, Portararo P, Gulino A, Consonni FM, Sica A, **Randon G**, Di Nicola M, Tripodo C, Colombo MP. SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities. *Front Immunol.* 2019 Jun 20;10:1369. doi: 10.3389/fimmu.2019.01369. PMID: 31281314; PMCID: PMC6596449.

13: Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, **Randon G**, De Braud F, Del Vecchio M. Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma. *Tumori.* 2019 Dec;105(6):465-473. doi: 10.1177/0300891619868009. Epub 2019 Aug 26. PMID: 31446882.

14: Raimondi A, **Randon G**, Sepe P, Claps M, Verzoni E, de Braud F, Procopio G. The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice. *Int J Mol Sci.* 2019 Aug 30;20(17):4263. doi: 10.3390/ijms20174263. PMID: 31480348; PMCID: PMC6747319.

15: Galli G, De Toma A, Pagani F, **Randon G**, Trevisan B, Prelaj A, Ferrara R, Proto C, Signorelli D, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G. Efficacy and safety of immunotherapy in elderly patients with

non-small cell lung cancer. *Lung Cancer*. 2019 Nov;137:38-42. doi: 10.1016/j.lungcan.2019.08.030. Epub 2019 Sep 10. PMID: 31526910.

16: Pagani F, **Randon G**, Guarini V, Raimondi A, Prisciandaro M, Lobefaro R, Di Bartolomeo M, Sozzi G, de Braud F, Gasparini P, Pietrantonio F. The Landscape of Actionable Gene Fusions in Colorectal Cancer. *Int J Mol Sci*. 2019 Oct 25;20(21):5319. doi: 10.3390/ijms20215319. PMID: 31731495; PMCID: PMC6861915.

17: Pietrantonio F, Lobefaro R, Antista M, Lonardi S, Raimondi A, Morano F, Mosconi S, Rimassa L, Murgioni S, Sartore-Bianchi A, Tomasello G, Longarini R, Farina G, Petrelli F, Gori S, **Randon G**, Corallo S, Pagani F, Guarini V, Palermo F, Martinetti A, Macagno M, Barault L, Perrone F, Tamborini E, Milione M, Di Nicolantonio F, Di Maio M, Fucà G, Di Bartolomeo M, de Braud F. Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. *Clin Cancer Res*. 2020 Mar 1;26(5):1017-1024. doi: 10.1158/1078-0432.CCR-19-3024. Epub 2019 Nov 18. PMID: 31740551.

18: Pietrantonio F, Yaeger R, Schrock AB, **Randon G**, Romero-Cordoba S, Rossini D, Fucà G, Ross JS, Kotani D, Madison R, Kim ST, Salvatore L, Raimondi A, Pagani F, Borelli B, Perrone F, Di Bartolomeo M, Miller VA, Ali SM, Lee J, Yoshino T, de Braud F, Falcone A, Hechtman JF, Cremolini C. Atypical RAS Mutations in Metastatic Colorectal Cancer. *JCO Precis Oncol*. 2019 Dec;3:1-11. doi: 10.1200/PO.19.00136. Erratum in: *JCO Precis Oncol*. 2022 Jul;6:e2200354. doi: 10.1200/PO.22.00354. PMID: 35100719; PMCID: PMC10445785.

19: Prelaj A, Ferrara R, Rebuzzi SE, Proto C, Signorelli D, Galli G, De Toma A, **Randon G**, Pagani F, Viscardi G, Brambilla M, Trevisan B, Ganzinelli M, Martinetti A, Gallucci R, Di Mauro RM, Molino G, Zilembo N, Torri V, de Braud FM, Garassino MC, Lo Russo G. EPSiLoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort. *Cancers (Basel)*. 2019 Dec 5;11(12):1954. doi: 10.3390/cancers11121954. PMID: 31817541; PMCID: PMC6966664.

20: Pietrantonio F, **Randon G**, Romagnoli D, Di Donato S, Benelli M, de Braud F. Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer. *Cancer Treat Rev*. 2020 Jan;82:101935. doi: 10.1016/j.ctrv.2019.101935. Epub 2019 Nov 28. PMID: 31821983.

21: Raimondi A, Sepe P, Claps M, Maccauro M, Aliberti G, Pagani F, Apollonio G, **Randon G**, Peverelli G, Seregini E, Verzoni E, Procopio G. Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori. *Tumori*. 2020 Oct;106(5):406-412. doi: 10.1177/0300891620905646. Epub 2020 Mar 2. PMID: 32116138.

22: Di Bartolomeo M, Morano F, Raimondi A, Miceli R, Corallo S, Tamborini E, Perrone F, Antista M, Niger M, Pellegrinelli A, **Randon G**, Pagani F, Martinetti A, Fucà G, Pietrantonio F; ITACA-S study group. Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. *Oncologist*. 2020 Mar;25(3):e460-e468. doi: 10.1634/theoncologist.2019-0471. Epub 2019 Nov 25. PMID: 32162808; PMCID: PMC7066701.

23: Prelaj A, Lo Russo G, Proto C, Signorelli D, Ferrara R, Galli G, De Toma A, **Randon G**, Pagani F, Trevisan B, Ganzinelli M, Zilembo N, Montrone M, Longo V, Pesola F, Pizzutillo P, Del Bene G, Varesano N, Galetta D, Torri V, Garassino MC, Di Maio M, Catino A. DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation. *Clin Lung Cancer*. 2020 Sep;21(5):e337-e348. doi: 10.1016/j.clcc.2020.01.005. Epub 2020 Mar 7. PMID: 32291212.

24: Pietrantonio F, Loupakis F, **Randon G**, Raimondi A, Salati M, Trapani D, Pagani F, Depetris I, Maddalena G, Morano F, Corallo S, Prisciandaro M, Corti F, Guarini V, Bocconi A, Marra A, Belli C, Spallanzani A, Fassan M, Lonardi S, Curigliano G, Fucà G, Di Bartolomeo M, de Braud F. Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High

Disease Burden. *Oncologist*. 2020 Sep;25(9):803-809. doi: 10.1634/theoncologist.2020-0014. Epub 2020 May 20. PMID: 32369650; PMCID: PMC7485362.

25: Pietrantonio F, Morano F, Niger M, Corallo S, Antista M, Raimondi A, Prisciandaro M, Pagani F, Prinzi N, Nichetti F, **Randon G**, Torchio M, Corti F, Ambrosini M, Palermo F, Palazzo M, Biamonte L, Platania M, Sposito C, Cosimelli M, Mazzaferro V, Pusceddu S, Cremolini C, de Braud F, Di Bartolomeo M. Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. *Clin Colorectal Cancer*. 2020 Sep;19(3):156-164. doi: 10.1016/j.clcc.2020.05.004. Epub 2020 May 23. PMID: 32513593; PMCID: PMC7245227.

26: Schirripa M, Nappo F, Cremolini C, Salvatore L, Rossini D, Bensi M, Businello G, Pietrantonio F, **Randon G**, Fucà G, Boccaccino A, Bergamo F, Lonardi S, Dei Tos AP, Fassan M, Loupakakis F. KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. *Clin Colorectal Cancer*. 2020 Sep;19(3):219-225. doi: 10.1016/j.clcc.2020.04.009. Epub 2020 May 12. PMID: 32605718.

27: **Randon G**, Pagani F, Pietrantonio F. MGMT Promoter Methylation as a Target In Metastatic Colorectal Cancer: Rapid Turnover and Use of Folates Alter its Study- Response. *Clin Cancer Res*. 2020 Jul 1;26(13):3495. doi: 10.1158/1078-0432.CCR-20-0817. PMID: 32611628.

28: Pietrantonio F, Fucà G, Manca P, Pagani F, Raimondi A, Prisciandaro M, **Randon G**, Corti F, de Braud F, Cremolini C, Miceli R. Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial. *Tumori*. 2021 Aug;107(4):353-359. doi: 10.1177/0300891620960808. Epub 2020 Oct 6. PMID: 33021466.

29: Mannavola F, Mandala M, Todisco A, Sileni VC, Palla M, Minisini AM, Pala L, Morgese F, Di Guardo L, Stucci LS, Guida M, Indini A, Quagliano P, Ferraresi V, Marconcini R, Tronconi MC, Rossi E, Nigro O, Occelli M, Cortellini A, Quadrini S, Palmieri G, Pigozzo J, Ascierto PA, Vitale MG, Strippoli S, Ferrucci PF, Berardi R, **Randon G**, Cardone P, Schinzari G, Silvestris F, Tucci M. An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. *Front Oncol*. 2020 Sep 15;10:1652. doi: 10.3389/fonc.2020.01652. PMID: 33042809; PMCID: PMC7523509.

30: Bersanelli M, Buti S, Giannarelli D, Leonetti A, Cortellini A, Russo GL, Signorelli D, Toschi L, Milella M, Pilotto S, Bria E, Proto C, Marinello A, **Randon G**, Rossi S, Vita E, Sartori G, D'Argento E, Qako E, Giaiacopi E, Ghilardi L, Bettini AC, Rapacchi E, Mazzoni F, Lavacchi D, Scotti V, Ciccone LP, De Tursi M, Di Marino P, Santini D, Russano M, Bordi P, Di Maio M, Audisio M, Filetti M, Giusti R, Berardi R, Fiordoliva I, Cerea G, Pizzutilo EG, Bearz A, De Carlo E, Cecere F, Renna D, Camisa R, Caruso G, Ficorella C, Banna GL, Cortinovis D, Brighenti M, Garassino MC, Tiseo M. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. *Lung Cancer*. 2020 Dec;150:123-131. doi: 10.1016/j.lungcan.2020.10.008. Epub 2020 Oct 22. PMID: 33130353.

31: Rutkowski P, Indini A, De Luca M, Merelli B, Mariuk-Jarema A, Teterycz P, Rogala P, Lugowska I, Cybulska-Stopa B, Labianca A, Di Guardo L, Del Vecchio M, Pigozzo J, **Randon G**, Corti F, Tondini CA, Rulli E, Mandala M. Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study. *J Immunother Cancer*. 2020 Nov;8(2):e001117. doi: 10.1136/jitc-2020-001117. PMID: 33203662; PMCID: PMC7674105.

32: Manca P, Corallo S, **Randon G**, Lonardi S, Cremolini C, Rimassa L, Bergamo F, Antoniotti C, Smiroldo V, Zaniboni A, Murialdo R, Tampellini M, Tomasello G, Clavarezza M, Racca P, Antista M, Raimondi A, Prisciandaro M, Pagani F, Palermo F, Greco FG, Vaiani M, Di Bartolomeo M, de Braud F, Calareso G, Morano F, Pietrantonio F. Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in

patients with RAS wild-type metastatic colorectal cancer. *Eur J Cancer*. 2021 Feb;144:31-40. doi: 10.1016/j.ejca.2020.11.017. Epub 2020 Dec 13. PMID: 33321462.

33: Raimondi A, Corallo S, Lonardi S, Antoniotti C, Rimassa L, Amatu A, Tampellini M, Racca P, Murialdo R, Clavarezza M, Zaniboni A, Toscano G, Tomasello G, Petrelli F, Antonuzzo L, Giordano M, Cinieri S, Longarini R, Niger M, Antista M, Ambrosini M, Pagani F, Prisciandaro M, **Randon G**, de Braud F, Di Bartolomeo M, Pietrantonio F, Morano F. Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. *Support Care Cancer*. 2021 Jul;29(7):3971-3980. doi: 10.1007/s00520-020-05972-2. Epub 2021 Jan 3. PMID: 33392769.

34: Manca P, Corallo S, Busico A, Lonardi S, Corti F, Antoniotti C, Procaccio L, Clavarezza M, Smirolto V, Tomasello G, Murialdo R, Sartore-Bianchi A, Racca P, Pagani F, **Randon G**, Martinetti A, Sottotetti E, Palermo F, Perrone F, Tamborini E, Prisciandaro M, Raimondi A, Di Bartolomeo M, Morano F, Pietrantonio F. The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer. *Clin Cancer Res*. 2021 May 1;27(9):2505-2514. doi: 10.1158/1078-0432.CCR-20-4699. Epub 2021 Feb 5. PMID: 33547199.

35: De Toma A, Lo Russo G, Signorelli D, Pagani F, **Randon G**, Galli G, Prelaj A, Ferrara R, Proto C, Ganzinelli M, Zilembo N, de Braud F, Garassino MC. Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. *Crit Rev Oncol Hematol*. 2021 Apr;160:103299. doi: 10.1016/j.critrevonc.2021.103299. Epub 2021 Mar 16. PMID: 33722699.

36: Vernieri C, Nichetti F, Lalli L, Moschetti L, Giorgi CA, Griguolo G, Marra A, **Randon G**, Rea CG, Ligorio F, Scagnoli S, De Angelis C, Molinelli C, Fabbri A, Ferraro E, Trapani D, Milani A, Agostinetto E, Bernocchi O, Catania G, Vantaggiato A, Palleschi M, Moretti A, Basile D, Cinausero M, Ajazi A, Castagnoli L, Lo Vullo S, Gerratana L, Puglisi F, La Verde N, Arpino G, Rocca A, Ciccarese M, Pedersini R, Fabi A, Generali D, Losurdo A, Montemurro F, Curigliano G, Del Mastro L, Michelotti A, Cortesi E, Guarneri V, Pruneri G, Mariani L, de Braud F. Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). *Clin Cancer Res*. 2021 Jun 15;27(12):3443-3455. doi: 10.1158/1078-0432.CCR-20-4928. Epub 2021 Mar 30. PMID: 33785482.

37: **Randon G**, Yaeger R, Hechtman JF, Manca P, Fucà G, Walch H, Lee J, Élez E, Seligmann J, Mussolin B, Pagani F, Germani MM, Ambrosini M, Rossini D, Ratti M, Salvà F, Richman SD, Wood H, Nanjangud G, Gloghini A, Milione M, Bardelli A, de Braud F, Morano F, Cremolini C, Pietrantonio F. EGFR Amplification in Metastatic Colorectal Cancer. *J Natl Cancer Inst*. 2021 Nov 2;113(11):1561-1569. doi: 10.1093/jnci/djab069. PMID: 33825902; PMCID: PMC8562951.

38: Fucà G, Beninato T, Bini M, Mazzeo L, Di Guardo L, Cimminiello C, **Randon G**, Apollonio G, Bisogno I, Del Vecchio M, Lauria Pantano C, Di Nicola M, de Braud F, Del Vecchio M. The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy. *Target Oncol*. 2021 Jul;16(4):529-536. doi: 10.1007/s11523-021-00819-0. Epub 2021 Jun 2. PMID: 34076798.

39: Di Guardo L, **Randon G**, Corti F, Vallacchi V, Raimondi A, Fucà G, Bini M, Maurichi A, Patuzzo R, Gallino G, Mattavelli I, Ruggeri R, Angi M, Cossa M, Valeri B, Cimminiello C, Santinami M, Rivoltini L, de Braud F, Rodolfo M, Vecchio MD. Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma. *Oncologist*. 2021 Dec;26(12):1079-1084. doi: 10.1002/onco.13926. Epub 2021 Sep 21. PMID: 34355463; PMCID: PMC8649022.

40: Antoniotti C, Korn WM, Marmorino F, Rossini D, Lonardi S, Masi G, **Randon G**, Conca V, Boccaccino A, Tomasello G, Passardi A, Swensen J, Ugolini C, Oberley M, Tamburini E, Casagrande M, Domenyuk V, Fontanini G, Giordano M, Abraham J, Spetzler D, Falcone A, Lenz HJ, Cremolini C. Tumour mutational burden, microsatellite

instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. *Eur J Cancer*. 2021 Sep;155:73-84. doi: 10.1016/j.ejca.2021.06.037. Epub 2021 Aug 5. PMID: 34365081.

41: Manca P, Corallo S, Lonardi S, Fucà G, Busico A, Leone AG, Corti F, Antoniotti C, Procaccio L, Smirardo V, Ratti M, Murialdo R, Racca P, Pagani F, **Randon G**, Martinetti A, Sottotetti E, Prisciandaro M, Ambrosini M, Raimondi A, Morano F, Pietrantonio F. Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study. *Br J Cancer*. 2022 Feb;126(3):449-455. doi: 10.1038/s41416-021-01591-8. Epub 2021 Nov 22. PMID: 34811502; PMCID: PMC8810873.

42: **Randon G**, Intini R, Cremolini C, Elez E, Overman MJ, Lee J, Manca P, Bergamo F, Pagani F, Antista M, Angerilli V, Ros Montaña FJ, Lavacchi D, Boccaccino A, Fucà G, Brich S, Cattaneo L, Fassan M, Pietrantonio F, Lonardi S. Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer. *Eur J Cancer*. 2022 Jan;161:90-98. doi: 10.1016/j.ejca.2021.11.018. Epub 2021 Dec 18. PMID: 34933155.

43: Fucà G, Cohen R, Lonardi S, Shitara K, Elez ME, Fakih M, Chao J, Klempner SJ, Emmett M, Jayachandran P, Bergamo F, García MD, Mazzoli G, Provenzano L, Colle R, Svrcek M, Ambrosini M, **Randon G**, Shah AT, Salati M, Fenocchio E, Salvatore L, Chida K, Kawazoe A, Conca V, Curigliano G, Corti F, Cremolini C, Overman M, Andre T, Pietrantonio F. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. *J Immunother Cancer*. 2022 Feb;10(2):e004001. doi: 10.1136/jitc-2021-004001. PMID: 35110358; PMCID: PMC8811606.

44: Prisciandaro M, Antista M, Raimondi A, Corti F, Morano F, Centonze G, Sabella G, Mangogna A, **Randon G**, Pagani F, Prinzi N, Niger M, Corallo S, Castiglioni di Caronno E, Massafra M, Bartolomeo MD, de Braud F, Milione M, Pusceddu S. Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective. *Front Oncol*. 2022 Feb 4;12:780716. doi: 10.3389/fonc.2022.780716. PMID: 35186729; PMCID: PMC8856722.

45: Morano F, Raimondi A, Pagani F, Lonardi S, Salvatore L, Cremolini C, Murgioni S, **Randon G**, Palermo F, Antonuzzo L, Pella N, Racca P, Prisciandaro M, Niger M, Corti F, Bergamo F, Zaniboni A, Ratti M, Palazzo M, Cagnazzo C, Ceglie MA, Marmorino F, Capone I, Conca E, Busico A, Brich S, Tamborini E, Perrone F, Di Maio M, Milione M, Di Bartolomeo M, de Braud F, Pietrantonio F. Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial. *J Clin Oncol*. 2022 May 10;40(14):1562-1573. doi: 10.1200/JCO.21.02583. Epub 2022 Mar 8. PMID: 35258987; PMCID: PMC9084437.

46: Ambrosini M, Del Re M, Manca P, Hendifar A, Drilon A, Harada G, Ree AH, Klempner S, Mølandsmo GM, Flatmark K, Russnes HG, Cleary JM, Singh H, Sottotetti E, Martinetti A, **Randon G**, Sartore-Bianchi A, Capone I, Milione M, Di Bartolomeo M, Pietrantonio F. ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series. *JCO Precis Oncol*. 2022 Apr;6(1):e2200015. doi: 10.1200/PO.22.00015. PMID: 35476549; PMCID: PMC9200393.

47: **Randon G**, Maddalena G, Germani MM, Pircher CC, Manca P, Bergamo F, Giordano M, Sposetti C, Montagna A, Vetere G, Zambelli L, Rasola C, Boccaccino A, Pagani F, Ambrosini M, Massafra M, Fontanini G, Milione M, Fassan M, Cremolini C, Lonardi S, Pietrantonio F. Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy. *JCO Precis Oncol*. 2022 Apr;6:e2200037. doi: 10.1200/PO.22.00037. Erratum in: *JCO Precis Oncol*. 2022 Jul;6:e2200356. doi: 10.1200/PO.22.00356. PMID: 35544729; PMCID: PMC9200389.

48: Rossini D, Germani MM, Lonardi S, Pietrantonio F, Dell'Aquila E, Borelli B, Allegrini G, Maddalena G, **Randon G**, Marmorino F, Zaniboni A, Buonadonna A, Boccaccino A, Conca V, Antoniotti C, Passardi A, Masi G, Cremolini C. Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and

TRIBE2 studies. *Eur J Cancer*. 2022 Jul;170:64-72. doi: 10.1016/j.ejca.2022.04.019. Epub 2022 May 17. PMID: 35594613.

49: Rossini D, Antoniotti C, Lonardi S, Pietrantonio F, Moretto R, Antonuzzo L, Boccaccino A, Morano F, Brugia M, Pozzo C, Marmorino F, Bergamo F, Tamburini E, Passardi A, **Randon G**, Murgioni S, Borelli B, Buonadonna A, Giordano M, Fontanini G, Conca V, Formica V, Aglietta M, Bordonaro R, Aprile G, Masi G, Boni L, Cremolini C. Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. *J Clin Oncol*. 2022 Sep 1;40(25):2878-2888. doi: 10.1200/JCO.22.00839. Epub 2022 Jun 6. PMID: 35666229; PMCID: PMC9426812.

50: Raimondi A, **Randon G**, Prisciandaro M, Pagani F, Lonardi S, Antoniotti C, Bozzarelli S, Sartore-Bianchi A, Tampellini M, Fanchini L, Murialdo R, Clavarezza M, Zaniboni A, Berenato R, Ratti M, Petrelli F, Antonuzzo L, Giordano M, Rossi A, Di Bartolomeo M, Di Maio M, Pietrantonio F, Morano F. Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial. *Int J Cancer*. 2022 Nov 15;151(10):1760-1769. doi: 10.1002/ijc.34156. Epub 2022 Jun 23. PMID: 35678328.

51: Elez E, Ros J, Fernández J, Villacampa G, Moreno-Cárdenas AB, Arenillas C, Bernatowicz K, Comas R, Li S, Kodack DP, Fasani R, Garcia A, Gonzalo-Ruiz J, Piris-Gimenez A, Nuciforo P, Kerr G, Intini R, Montagna A, Germani MM, **Randon G**, Vivancos A, Smits R, Graus D, Perez-Lopez R, Cremolini C, Lonardi S, Pietrantonio F, Dienstmann R, Tabernero J, Toledo RA. RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer. *Nat Med*. 2022 Oct;28(10):2162-2170. doi: 10.1038/s41591-022-01976-z. Epub 2022 Sep 12. PMID: 36097219; PMCID: PMC9556333.

52: Manca P, Corti F, Intini R, Mazzoli G, Miceli R, Germani MM, Bergamo F, Ambrosini M, Cristarella E, Cerantola R, Boccaccio C, Ricagno G, Ghelardi F, **Randon G**, Leoncini G, Milione M, Fassan M, Cremolini C, Lonardi S, Pietrantonio F. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors. *Eur J Cancer*. 2023 Jul;187:15-24. doi: 10.1016/j.ejca.2023.03.029. Epub 2023 Mar 31. PMID: 37099945.

53: **Randon G**, Aoki Y, Cohen R, Provenzano L, Nasca V, Klempner SJ, Maron SB, Cerantola R, Chao J, Fornaro L, Ferrari Bravo W, Ghelardi F, Ambrosini M, Manca P, Salati M, Kawazoe A, Zhu V, Cowzer D, Genovesi V, Lonardi S, Shitara K, André T, Pietrantonio F. Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade. *J Immunother Cancer*. 2023 Jun;11(6):e007104. doi: 10.1136/jitc-2023-007104. PMID: 37277193; PMCID: PMC10255232.

54: Raimondi A, Nichetti F, Stahler A, Wasan HS, Aranda E, **Randon G**, Kurreck A, Meade AM, Díaz-Rubio E, Niger M, Stintzing S, Palermo F, Trarbach T, Prisciandaro M, Sommerhäuser G, Fisher D, Morano F, Pietrantonio F, Modest DP. Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual data pooled analysis of randomised clinical trials. *Eur J Cancer*. 2023 Sep;190:112945. doi: 10.1016/j.ejca.2023.112945. Epub 2023 Jun 19. PMID: 37441940.

55: **Randon G**, Pietrantonio F. Towards Multiomics-Based Dissection of Anti-EGFR Sensitivity in Colorectal Cancer. *Clin Cancer Res*. 2023 Oct 13;29(20):4021-4023. doi: 10.1158/1078-0432.CCR-23-1954. PMID: 37594733; PMCID: PMC10570674.

56: **Randon G**, Nakamura Y, Yaeger R, Lonardi S, Cremolini C, Elez E, Nichetti F, Ghelardi F, Nasca V, Bergamo F, Conca V, Ros J, Bando H, Maddalena G, Oldani S, Prisciandaro M, Raimondi A, Schrock AB, Agnelli L, Walch H, Yoshino T, Pietrantonio F. Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic

Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study. Clin Cancer Res. 2024 Jan 17;30(2):436-443. doi: 10.1158/1078-0432.CCR-23-1379. PMID: 37610454; PMCID: PMC10792357.

57: Ghelardi F, Raimondi A, Morano F, **Randon G**, Pannone A, Guaglio M, Mazzoli G, Nasca V, Milione M, Leoncini G, Sabella G, Greco GF, Lampis BR, Galassi M, Delfanti S, Nannini M, Intini R, Baratti D, Di Bartolomeo M, Deraco M, Pietrantonio F. Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin. Clin Colorectal Cancer. 2023 Dec;22(4):450-456.e1. doi: 10.1016/j.clcc.2023.08.005. Epub 2023 Aug 11. PMID: 37657955.

58: Pretta A, Ziranu P, Giampieri R, Pinna G, **Randon G**, Donisi C, Ravarino A, Loi F, Deias G, Palmas E, Pretta G, Morano F, Semonella F, Mariani S, Deidda MA, Pusceddu V, Puzzone M, Lai E, Solinas C, Restivo A, Zorcolo L, Barbara R, Berardi R, Faa G, Pietrantonio F, Scartozzi M. Mismatch Repair system protein deficiency as a resistance factor for locally advanced rectal adenocarcinoma patients receiving neoadjuvant chemo-radiotherapy. Br J Cancer. 2023 Nov;129(10):1619-1624. doi: 10.1038/s41416-023-02444-2. Epub 2023 Sep 25. PMID: 37749283; PMCID: PMC10646038.

59: Corti F, Brizzi MP, Amoroso V, Giuffrida D, Panzuto F, Campana D, Prinzi N, Milione M, Cascella T, Spreafico C, **Randon G**, Oldani S, Leporati R, Scotto G, Pulice I, Stocchetti BL, Porcu L, Coppa J, Di Bartolomeo M, de Braud F, Pusceddu S. Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial. BMC Cancer. 2023 Sep 26;23(1):908. doi: 10.1186/s12885-023-11287-2. PMID: 37752423; PMCID: PMC10523723.

60: Moretto R, Germani MM, Ros J, Daniel F, Ghelardi F, Vetere G, Giordano M, Toledo RA, Bergamo F, **Randon G**, Elez E, Lonardi S, Pietrantonio F, Vignali P, Rossini D, Matito J, Ugolini C, Fontanini G, Masi G, Cremolini C. Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy. JCO Precis Oncol. 2023 Sep;7:e2300255. doi: 10.1200/PO.23.00255. PMID: 37797285.

61: Raimondi A, Kim YW, Kang WK, Langley RE, Choi YY, Kim KM, Nankivell MG, **Randon G**, Kook MC, An JY, Grabsch HI, Prisciandaro M, Nichetti F, Noh SH, Sohn TS, Kim S, Wotherspoon A, Morano F, Cunningham D, Lee J, Cheong JH, Smyth EC, Pietrantonio F. Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials. Eur J Cancer. 2024 May;203:114043. doi: 10.1016/j.ejca.2024.114043. Epub 2024 Apr 4. PMID: 38598921.

62: Ghelardi F, Fucà G, Cavalli C, Shitara K, Cohen R, Ambrosini M, Maron SB, Cerantola R, Nasca V, Liberti GD, Zambelli L, Palazzo M, Salati M, Aoki Y, Kawazoe A, Cowzer D, Lonardi S, André T, **Randon G**, Pietrantonio F. The Prognostic Nutritional Index in patients with microsatellite instability-high metastatic gastric or gastroesophageal cancers receiving immune checkpoint inhibitors. Dig Liver Dis. 2024 May 20:S1590-8658(24)00744-8. doi:10.1016/j.dld.2024.05.005. Epub ahead of print. PMID: 38772790.

63: Sorrentino L, Daveri E, Belli F, Vigorito R, Battaglia L, Sabella G, Patti F, **Randon G**, Pietrantonio F, Vernieri C, Scaramuzza D, Villa S, Milione M, Gronchi A, Cosimelli M, Guaglio M. Management of patients with locally recurrent rectal cancer with a previous history of distant metastases: retrospective cohort study. BJS Open. 2024 May 8;8(3):zrae061. doi: 10.1093/bjsopen/zrae061. PMID: 38869237; PMCID: PMC11170501.

64: Bodalal Z, Hong EK, Trebeschi S, Kurilova I, Landolfi F, Bogveradze N, Castagnoli F, **Randon G**, Snaebjornsson P, Pietrantonio F, Lee JM, Beets G, Beets- Tan R. Non-invasive CT radiomic biomarkers predict microsatellite stability status in colorectal cancer: a multicenter validation study. Eur Radiol Exp. 2024 Aug 26;8(1):98. doi: 10.1186/s41747-024-00484-8. PMID: 39186200; PMCID: PMC11347521.

65: **Randon G**, Lonardi S, Fassan M, Palermo F, Tamperi S, Giommoni E, Ceccon C, Di Donato S, Fornaro L, Brunetti O, De Vita F, Bittoni A, Chini C, Spallanzani A, Nappo F, Bethaz V, Strippoli A, Latiano T, Cardellino GG, Giuliani F, Morano F, Niger M, Raimondi A, Prisciandaro M, Pircher CC, Sciortino C, Marchesi S, Garattini SK, Airò

G, Miceli R, Di Bartolomeo M, Pietrantonio F. Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial. *Lancet Oncol.* 2024 Nov 15;S1470-2045(24)00580-1. doi: 10.1016/S1470-2045(24)00580-1. Epub ahead of print. PMID: 39557058.

Relatore o presentazione di poster a conferenze

- 1: Poster presenter at the AACR 2022, New Orleans, Louisiana, USA. April 8-13, 2022. Abstract #1269. "Negative ultra-selection of patients with RAS/BRAF wild-type (wt), microsatellite stable (MSS) metastatic colorectal cancer (mCRC) receiving anti-EGFR-based therapy: The PRESSING2 study"
- 2: Speaker at Star Network 2022, La Spezia, Italy. December 1-2, 2022.
- 3: Speaker at "Highlights in Gastrointestinal cancer Prato 2023", Prato, Italy. April 13-14, 2023.
- 4: Speaker at ESMO World Congress on Gastrointestinal Cancer 2023, Barcelona, Spain. Jun 28 – Jul 1, 2023.**
- 5: Speaker at "From Orlando to Palermo. News from AACR Annual Meeting", Palermo, Italy. May 5-6, 2023.
- 6: Speaker at "La ricerca e la cura: UPDATE 2023 Virtual Meeting. September 21-22, 2023.
- 7: Speaker at "Star Network 2023", La Spezia, Italy. Nov 29-30, 2023.
- 8: Speaker at ESMO Gastrointestinal Cancers Congress 2024, Munich, Bayern, Germany. Jun 26-29, 2024.**
- 9: Speaker at "La Natura della cultura in Oncologia", Pesaro, Italy. Oct 11-12, 2024.
- 10: Speaker at: "Le neoplasie gastriche: un percorso condiviso". Fermo, Italy. Oct 18, 2024.
- 11: Speaker at: "La chirurgia oncologica dell'apparato digerente: tra elezione ed urgenza". Varese, Italy. November 15, 2024.